News
10-22-2013, 10:30 PM
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), announced that the complete analysis results of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.
More... (http://www.news-medical.net/news/20131023/Angiochem-presents-results-of-Phase-2-study-with-ANG1005-in-breast-cancer-patients-with-brain-metastases.aspx)
More... (http://www.news-medical.net/news/20131023/Angiochem-presents-results-of-Phase-2-study-with-ANG1005-in-breast-cancer-patients-with-brain-metastases.aspx)